Now, investigators at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo have uncovered how ...

While the allogeneic vs autologous debate continues in the cell therapy field, research on in vivo therapies is drawing ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

For the 80 million people worldwide with celiac disease, the only treatment available is to cut grains like pasta and bread out of their lives. | For the 80 million people worldwide who have celiac ...

Frequent mutations of SARS-CoV-2 have reduced the effectiveness of vaccines, highlighting the need for mutation-resistant ...

They also show that models learned from nonsynonymous mutations and from out-of-frame sequences are different, prompting new questions about germinal center function. Strengths of the study include an ...

A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to ...

An in-depth analysis of ER+ breast cancer, focusing on its prevalence, molecular biology, current treatments, and emerging ...

In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and ...